Differential hRad17 expression by histologic subtype of ovarian cancer

Journal of Ovarian Research

Volumn 4, Issue 1, 2011, Pages

  Young, Jennifer L ^b   Koon, E Colin ^c   Kwong, Joseph ^d   Welch, William R ^a   Muto, Michael G ^a   Berkowitz, Ross S ^a   Mok, Samuel C ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; HRAD17 PROTEIN; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CELL LYSATE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RNA EXTRACTION; TISSUE SECTION; WESTERN BLOTTING;

EID: 79953091007     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-4-6     Document Type: Article

References (28)

1. Cancer statistics, 2006. A Jemal R Siegel E Ward T Murray J Xu C Smigal MJ Thun, CA Cancer J Clin 2006 56 106 130 10.3322/canjclin.56.2.106 16514137
2. Potential markers that complement expression of CA125 in epithelial ovarian cancer. DG Rosen L Wang JN Atkinson Y Yu KH Lu EP Diamandis I Hellstrom SC Mok J Liu RC Bast Jr, Gynecol Oncol 2005 99 267 277 10.1016/j.ygyno.2005.06. 040 16061277 (Pubitemid 41502830)
3. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. JO Schorge RD Drake H Lee SJ Skates R Rajanbabu DS Miller J-H Kim DW Cramer RS Berkowitz SC Mok, Clin Cancer Res 2004 10 3474 3478 10.1158/1078-0432.CCR-03- 0365 15161704 (Pubitemid 38685455)
4. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. SC Mok J Chao S Skates K Wong GK Yiu MG Muto RS Berkowitz DW Cramer, J Natl Cancer Inst 2001 93 1458 1464 10.1093/jnci/93.19. 1458 11584061 (Pubitemid 32982674)
5. New technologies for the identification of markers for early detection of ovarian cancer. CA Bandera B Ye SC Mok, Curr Opin Obstet Gynecol 2003 15 51 55 10.1097/00001703-200302000-00008 12544502 (Pubitemid 36143493)
6. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. KK Wong RS Cheng SC Mok, Biotechniques 2001 30 670 675 11252802 (Pubitemid 32202873)
7. HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. S Bao MS Chang D Auclair Y Sun Y Wang WK Wong J Zhang Y Liu X Qian R Sutherland,, et al. Cancer Res 1999 59 2023 2028 10232579 (Pubitemid 29217656)
8. Identification of a human homologue of the Schizosaccharomyces pombe rad17+ checkpoint gene.[erratum appears in J Biol Chem 1999 Aug 20;274(34):24438]. AE Parker I Van de Weyer MC Laus P Verhasselt WH Luyten, J Biol Chem 1998 273 18340 18346 10.1074/jbc.273.29.18340 9660800
9. hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation. L Li CA Peterson G Kanter-Smoler YF Wei LS Ramagli P Sunnerhagen MJ Siciliano RJ Legerski, Oncogene 1999 18 1689 1699 10.1038/sj.onc.1202469 10208430 (Pubitemid 29137460)
10. The human checkpoint Rad protein Rad17 is chromatin-associated throughout the cell cycle, localizes to DNA replication sites, and interacts with DNA polymerase epsilon. SM Post AE Tomkinson EYHP Lee, Nucleic Acids Res 2003 31 5568 5575 10.1093/nar/gkg765 14500819 (Pubitemid 37441927)
11. HRad17 colocalizes with NHP2L1 in the nucleolus and redistributes after UV irradiation. MS Chang H Sasaki MS Campbell SK Kraeft R Sutherland CY Yang Y Liu D Auclair L Hao H Sonoda,, et al. J Biol Chem 1999 274 36544 36549 10.1074/jbc.274.51.36544 10593953
12. ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses. S Bao RS Tibbetts KM Brumbaugh Y Fang DA Richardson A Ali SM Chen RT Abraham XF Wang, Nature 2001 411 969 974 10.1038/35082110 11418864 (Pubitemid 32601496)
13. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body. A Nabetani O Yokoyama F Ishikawa, J Biol Chem 2004 279 25849 25857 10.1074/jbc.M312652200 15075340 (Pubitemid 38756850)
14. Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. X Wang L Wang MD Callister JB Putnam L Mao L Li, Cancer Res 2001 61 7417 7421 11606373 (Pubitemid 32995027)
15. Phosphorylation of serines 635 and 645 of human Rad17 is cell cycle regulated and is required for G(1)/S checkpoint activation in response to DNA damage. S Post YC Weng K Cimprich LB Chen Y Xu EY Lee, Proc Natl Acad Sci USA 2001 98 13102 13107 10.1073/pnas.231364598 11687627 (Pubitemid 33051324)
16. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. VP Bermudez LA Lindsey-Boltz AJ Cesare Y Maniwa JD Griffith J Hurwitz A Sancar, Proc Natl Acad Sci USA 2003 100 1633 1638 10.1073/pnas.0437927100 12578958 (Pubitemid 36254499)
17. The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9. M Rauen MA Burtelow VM Dufault LM Karnitz, J Biol Chem 2000 275 29767 29771 10.1074/jbc.M005782200 10884395 (Pubitemid 32043860)
18. Structures of the human Rad17-replication factor C and checkpoint Rad 9-1-1 complexes visualized by glycerol spray/low voltage microscopy. JD Griffith LA Lindsey-Boltz A Sancar, J Biol Chem 2002 277 15233 15236 10.1074/jbc.C200129200 11907025 (Pubitemid 34967782)
19. Purification and characterization of human DNA damage checkpoint Rad complexes. LA Lindsey-Boltz VP Bermudez J Hurwitz A Sancar, Proc Natl Acad Sci USA 2001 98 11236 11241 10.1073/pnas.201373498 11572977 (Pubitemid 32928712)
20. A conserved physical and functional interaction between the cell cycle checkpoint clamp loader and DNA ligase I of eukaryotes. W Song DS Levin J Varkey S Post VP Bermudez J Hurwitz AE Tomkinson, J Biol Chem 2007 282 22721 22730 10.1074/jbc.M703774200 17561505 (Pubitemid 47267306)
21. Disruption of the Rad9/Rad1/Hus1 (9-1-1) complex leads to checkpoint signaling and replication defects. S Bao T Lu X Wang H Zheng L-E Wang Q Wei WN Hittelman L Li, Oncogene 2004 23 5586 5593 10.1038/sj.onc.1207753 15184880 (Pubitemid 39093036)
22. Interaction between human MCM7 and Rad17 proteins is required for replication checkpoint signaling. C-C Tsao C Geisen RT Abraham, Embo J 2004 23 4660 4669 10.1038/sj.emboj.7600463 15538388 (Pubitemid 39657865)
23. G2 checkpoint abrogators as anticancer drugs. T Kawabe, Mol Cancer Ther 2004 3 513 519 15078995
24. Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis. A Kataoka N Sadanaga K Mimori H Ueo GF Barnard K Sugimachi D Auclair LB Chen M Mori, Clin Cancer Res 2001 7 2815 2820 11555598 (Pubitemid 32911390)
25. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). SW Tsao SC Mok EG Fey JA Fletcher TS Wan EC Chew MG Muto RC Knapp RS Berkowitz, Exp Cell Res 1995 218 499 507 10.1006/excr.1995.1184 7796885
26. Characterisation of human kallikrein 6/protease M expression in ovarian cancer.[erratum appears in Br J Cancer. 2005 Mar 14;92(5):983]. X Ni W Zhang KC Huang Y Wang SK Ng SC Mok RS Berkowitz SW Ng, Br J Cancer 2004 91 725 731 15305183 (Pubitemid 39141632)
27. Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis. H Sasaki LB Chen D Auclair S Moriyama M Kaji I Fukai M Kiriyama Y Yamakawa Y Fujii, Lung Cancer 2001 34 47 52 10.1016/S0169-5002(01) 00223-9 11557112 (Pubitemid 32824122)
28. Downregulation of RAD17 in head and neck cancer. M Zhao S Begum PK Ha W Westra J Califano, Head Neck 2008 30 35 42 10.1002/hed.20660 17657792 (Pubitemid 351158319)